2025 annual financial data
CRISPR Therapeutics 2025 Operating margin
CRISPR Therapeutics 2025 operating margin with verified reported values.
Direct answer
Operating margin was -16,191.4%.
Operating income was -568,318,000 USD and net income was -581,599,000 USD.
Operating cash flow was -345,014,000 USD.
Get free CRISPR Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 3,510,000 USD
- Operating income
- -568,318,000 USD
- Net income
- -581,599,000 USD
- Operating cash flow
- -345,014,000 USD